

VIAGENPUMATUCEL-L (HS-110) PLUS NIVOLUMAB IN PATIENTS WITH ADVANCED NON-SMALL LUNG CANCER (NSCLC)

Daniel Morgensztern¹, Lyudmila Bazhenova², Saiana N Waqar¹, Lori McDermott³, Jeff Hutchins³, Wael Harb⁴, Vamsidar Velcheti⁵, Roger B. Cohen⁶

¹Washington University School of Medicine, St. Louis, MO; ²UC San Diego, Moores Cancer center, San Diego, CA; ³Heat Biologics, Inc, Durham, NC; ⁴Horizon Oncology Center, Lafayette, IN; ⁵Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; ⁶University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

Background

Viagenpumatucel-L (HS-110) is an allogeneic cellular immunotherapy that incorporates a broad range of tumor antigens that are known to be shared amongst a high proportion of patients with non-small cell lung cancer (NSCLC). This cell system contains HLA-A1 (a human histocompatibility surface antigen) for purposes of drug identity and gp96-Ig (a transgene constructed from sequences encoding the human gp96 gene with the C-terminal KDEL sequence removed and replaced with the Fc portion of human IgG1). This construct is designed to enable the cell to express the heat shock protein/adjutant gp96 in secreted form. The secreted gp96 acts as a chaperone and adjuvant to induce cellular immune responses to various tumor antigens expressed by the host cell. These characteristics make gp96 unique because it can both activate (MHC and T-cell costimulator up-regulation) and deliver chaperoned antigens to an APC for display via MHC, in order to elicit CD8⁺ T-cell mediated immune responses^{1,2}. The HS-110-102 "Durga" Trial is an exploratory, multi-cohort master protocol evaluating HS-110 in combination with anti-PD1 mAbs in the treatment of advanced non-small lung cancer. Here we present interim data from the first two cohorts, A and B, for all patients enrolled on or before the efficacy data cut-off. Cohort A (n=42) consists of previously treated patients who have never received an immune checkpoint inhibitor (CPI). Cohort B (n=20) is comprised of patients with progressive disease (PD) after receiving a minimum of 4 months of CPI therapy at any time prior to study entry.

Trial ID: NCT02439450


Mechanism of Action



Figure 1: Viagenpumatucel-L (HS-110) Mechanism of Action

HS-110 is developed from the AD100 lung adenocarcinoma cell line transfected with gp96-Ig, where the gp96 KDEL ER retention sequence is replaced by IgG1 Fc. Gp96-Ig acts as a chaperone protein for tumor associated antigens that is recognized by CD81 on APCs, resulting in cross-presentation of antigen to MHC I for the selection of antigen-specific CD8 cells. At the same time, Gp96-Ig binding to TLR2 and 4 leads to upregulation of co-stimulatory molecules, MHC II and secretion of cytokines and chemokines.

Study Design and Endpoints



Primary Endpoints
Ph 1b: Safety
Ph 2: ORR (RECIST 1.1)
Secondary Endpoints
OS, PFS, DCR, DOR and RECIST measurements
Exploratory Endpoints
Immune response, and correlation of clinical outcomes with Baseline CD8⁺ TIL levels, and PD-L1 expression on tumor cells.

Figure 2: Study Design

This single-arm, open-label trial has a phase 1b portion of 15 previously treated patients that have never received a CPI with a phase 2 expansion, that added Cohort B: Patients with PD after treatment failure with CPI.

Study Schema




Figure 3: HS110-102 Study Schema

Patients receive weekly HS-110 (1×10^7 cells) intradermally for 18 weeks via 5 injections of 0.1ml each, and biweekly nivolumab 240 mg IV until disease progression or unacceptable toxicity.

Patient Characteristics

	Cohort A (N = 44)	Cohort B (N = 31)
Median age (range)	65 (37-87)	66 (50-84)
Female gender	24 (55%)	18 (58%)
White race	39 (89%)	25 (81%)
ECOG PS 1	27 (61%)	11 (35%)
EGFR or ALK positive	9 (20%)	3 (10%)
Histology		
Adeno	41 (93%)	25 (81%)
Squamous	3 (7%)	6 (19%)
Smoking status		
Current/past	37 (84%)	27 (87%)
Never	7 (16%)	4 (13%)
Prior lines of tx		
1	27 (61%)	5 (16%)
2 or more	13 (30%)	18 (58%)
Unavailable	4 (9%)	8 (26%)
PD-L1		
< 1%	17 (39%)	8 (26%)
≥ 1%	13 (29%)	14 (45%)
Unavailable	14 (32%)	9 (29%)
CD8 ⁺ TIL		
≤ 10%	12 (27%)	9 (29%)
> 10%	24 (55%)	10 (32%)
Unavailable	8 (18%)	12 (39%)

Table 1: Patient Characteristics

Baseline patient demographics of the safety population (n=75). Note that only the patients enrolled prior to the data cut-off were included in the efficacy population (n=62).

Cohort A (CPI naïve): Objective Response Rate




Figure 4: Best Target Lesion Response

Waterfall plot of best target lesion response using percent change from baseline of the SLD (sum of longest diameters) for all patients who received at least 1 post-baseline scan (n=38).

Cohort A (CPI naïve): Overall Survival & Tumor Burden





Figure 5a: Overall Survival

KM plot of patient survival (n=42). The vertical hash marks represents patient censoring. Median follow up of 14.4 months with 60% of patients still alive.

Figure 5b: Changes in Tumor Burden from Baseline

Waterfall plot of tumor kinetics (n=42) demonstrating durability of decreased burden.




Low CD8 ⁺ TIL (≤10%)		High CD8 ⁺ TIL (>10%)	
Median OS	NR	NR	NR
12 month OS	75%	50%	44%
HR 0.39 (95% CI, 0.06-2.31)		HR 0.35 (95% CI, 0.26-2.79)	

Negative PD-L1 (<1%)		Positive PD-L1 (≥1%)	
Median OS	NR	NR	NR
12 month OS	44%	54%	54%
HR 0.85 (95% CI, 0.26-2.79)			

Figure 6: Overall Survival - Subgroup Analysis by CD8⁺ TIL and PD-L1 Levels

KM plot of patient survival (n=42) based on protocol-defined subgroups of CD8⁺ TIL (high and low) and PD-L1 status (positive and negative) at baseline. The vertical hash marks represents patient censoring.



Typical ISR

Adverse Events

Adverse events (AEs) occurring in ≥10% of patients in the safety population (n=75) are: fatigue (31%), cough (21%), diarrhea (15%), anemia (13%), dyspnea (13%), nausea (13%), pruritis (13%), arthralgia (12%), hypalbuminemia (12%), decreased appetite (11%), hyponatremia (11%), dizziness (11%) and constipation (11%). There were two grade 5 AEs, pulmonary embolism and acute myocardial infarction, neither of which were deemed related to treatment.

Cohort B (CPI progressors): Objective Response Rate




Figure 8: Best Target Lesion Response

Waterfall plot of best target lesion response using percent change from baseline of the SLD (sum of longest diameters) for all patients who received at least 1 post-baseline scan (n=18). The bar colors indicate the type of therapy received immediately preceding study entry. The numerical values presented with each bar indicate the number of lines of prior treatment.

*per investigator Assessment

Cohort B (CPI Progressors): Duration of Treatment




Figure 9: Duration of Treatment

Summary plot showing time on study and time of disease progression (n=20).




Figure 10: Progression Free Survival - Injection Site Reaction (ISR)

KM plot of patient progression free survival (n=20) with ISR subgroups (yes or no) shows progression-free survival benefit in patients experiencing at least one injection site reaction to HS-110 during study treatment.

Immune Activity and Response




Figure 11: Immune Activity and Survival

Peripheral blood obtained before and during treatment (Weeks 4, 7, 13, EOT; n=24) to measure HS-110 derived immune reactivity. ELISPOTs represent INF-γ secretion from T cells in culture after stimulation with HS-110 lysate. **High** = Patients with absolute ELISPOT increases **above** the group median; **Low** = Patients with absolute ELISPOT increases **below** the group median.




Figure 12: Changes in the Tumor Microenvironment

Using AQA FACS (CD3, K67, Granzyme B, PD-L1) and Inform (CD4, Foxp3) immunohistochemistry-based analysis, cell phenotypes were quantitated in the tumor microenvironment (TME) of a patient at baseline and after 10 weeks of combination treatment.

Conclusions

HS-110 in combination with nivolumab is well tolerated.

Preliminary results demonstrate the ability of HS-110 plus nivolumab to induce CD8⁺ T-cell tumor infiltration in previously "cold" tumors.

In Cohort A, the occurrence of injection site reactions and increased INF-γ ELISPOTs may be associated with improved overall survival.

In Cohort B, early data suggest that the addition of HS-110 to nivolumab may restore responsiveness after tumor progression on prior CPI.

References

1. Stribo N, Garcia-Soto A, Schreiber TH, Podack ER. Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer and infectious diseases. Immunologic research 2013;57:311-25.
2. Stribo N, Vaccari M, Pahwa S, et al. Novel vaccination modality provides significant protection against mucosal infection by highly pathogenic HIV. Journal of immunology (Baltimore, Md. : 1950) 2013;190:2495-9.

Acknowledgements

The authors are grateful for the investigators, study staff, patients and their families for the commitment to this trial to help advance the treatment of non-small cell lung cancer.

For study-related correspondence, contact lmcdermott@heatbiologics.com